Soligenix Shares Are Trading Lower After the Company Announced Clinical Results From a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-cell Lymphoma. The Stock Initially Traded Higher, but It Has Since Reversed.
Soligenix Shares Are Trading Lower After the Company Announced Clinical Results From a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-cell Lymphoma. The Stock Initially Traded Higher, but It Has Since Reversed.
Soligenix股票在公司公佈對比研究評估HyBryte和Valchlor治療皮膚T細胞淋巴瘤的臨床結果後交易下跌。該股票最初交易上漲，但隨後逆轉。
Soligenix Shares Are Trading Lower After the Company Announced Clinical Results From a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-cell Lymphoma. The Stock Initially Traded Higher, but It Has Since Reversed.
Soligenix股票在公司公佈對比研究評估HyBryte和Valchlor治療皮膚T細胞淋巴瘤的臨床結果後交易下跌。該股票最初交易上漲，但隨後逆轉。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。